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Acute blood pressure elevations are commonly
treated in hospitalized patients. There are no
guidelines for appropriate practice and no evi-
dence that such treatment is useful. The authors
performed a retrospective review of medical and
pharmacy records to determine how often intra-
venous hydralazine and labetalol are ordered and
administered. During a 1-year study period, a
total of 29,545 hospitalizations were recorded.
The authors identified 2189 patients (7.4% of all
patients) for whom 7242 orders were written for
hydralazine as needed (10–20 mg per dose) and
5915 for labetalol (10–20 mg per dose). Ordered
drugs were adminstered in 60.3% of patients,
and the average number of doses administered
was 5.38.2 (mean  SD) for hydralazine and
5.67.7 for labetalol. Hospital length of stay
(LOS) for patients for whom hydralazine was
ordered was 12.015.9 days for those who
received at least 1 dose and 7.19.0 days for
those who did not receive a dose (P<.001). For
patients for whom labetalol was ordered, patients
receiving at least 1 dose had an LOS of
11.816.1 days vs 7.910.4 days for those who
did not receive a dose (P<.001). Treatment of
elevated blood pressure in in-patients is a com-
mon practice. The authors suggest that evidence
is needed to determine whether the practice is of
benefit. J Clin Hypertens (Greenwich).
2010;12:29–33. ª2009 Wiley Periodicals, Inc.
The practice of lowering blood pressure (BP)acutely in ‘‘hypertensive urgencies’’ (generally
defined as sustained BP elevations above the
range of 110–120 mm Hg diastolic or 180–
200 mm Hg systolic without associated ongoing
target organ damage) and ‘‘emergencies’’ (simi-
larly elevated BPs associated with target organ
damage) is well accepted. However, recent litera-
ture reviews have failed to demonstrate a clear
benefit,1,2 and attempts to lower BP may result in
hypotension, which can cause adverse cardiovas-
cular events.3–5
Much more commonly encountered in in-patient
settings are nonsustained transient elevations of BP
to the range of ‘‘urgency,’’ and many physicians
routinely treat these acute elevations of BP in hospi-
talized patients with antihypertensives. Guidelines
for hypertension treatment6–9 are silent on the issue
of in-patient management of hypertension, and
there is no expert consensus recommendation to
our knowledge.
To begin an assessment of current practices
related to treatment of in-patient hypertension, we
undertook an analysis of the use of intravenous
antihypertensives in patients admitted to the
University of Michigan Hospital with primary diag-
noses other than hypertension. In this initial effort,
we focused on the use of intravenous low-dose
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hydralazine (10–20 mg) and labetalol (10–20 mg),
the two agents commonly employed in our hospital
for the treatment of hypertension that are not
routinely used for other conditions.
METHODS
The study was approved by the University of Mich-
igan institutional review board for human research
and met all Health Insurance Portability and
Accountability Act requirements.
Study Sample
A query of the hospital’s electronic data warehouse
was made to identify all patients 18 years and older
admitted to the University of Michigan Medical
Center from October 1, 2007, through September
30, 2008. Each separate admission during the study
period was counted as an event for patients with
multiple admissions. Patient characteristics obtained
included age, sex, and hospital length of stay
(LOS). Patients for whom intravenous labetalol
and ⁄or hydralazine orders were entered into the
hospital’s pharmacy system were identified for
study. Patients with principal diagnoses of hyper-
tension, ie, those admitted specifically for treatment
of hypertension, were excluded (International Clas-
sification of Diseases, Ninth Revision [ICD-9]
codes 401.0, 401.1, 401.9, 405.0). We also deter-
mined which patients had admission diagnoses cor-
responding to accepted indications for aggressive
antihypertensive therapy if necessary10: ICD-9
codes 437.2 (hypertensive encephalopathy), 436
(cerebral vascular accident ⁄cerebral infarction),
430, 431, 432.0 to 432.9 (subarachnoid hemor-
rhage), 428.1 (acute left ventricular dysfunction),
506.1, 518.4 (acute pulmonary edema), and 441.0
to 441.3 (aortic dissection). We did not include
preeclampsia in this analysis.
Medication data included identification of
all orders written and entered into the hospital
pharmacy system, including the name of the medi-
cation, directions for frequency of use, and the
number of doses administered during the hospital
stay.
Analysis
Descriptive statistics of mean and standard devia-
tion (SD) for continuous variables and frequency
with percent for categoric data were used to
describe the sample characteristics. Comparisons of
the use of specific agents based on patient charac-
teristics were conducted using Student t test and
1-way analysis of variance (ANOVA) with Scheffe
correction. P values of .05 were considered
statistically significant. Statistical analyses were con-
ducted using SPSS version 16.0 (SPSS, Chicago, IL).
RESULTS
During the study period (August 1, 2007, to Sep-
tember 30, 2008) there were 29,545 adult admis-
sions to the University of Michigan Hospital. We
identified 2189 patients (7.4% of all admissions)
for whom intravenous hydralazine or labetalol was
ordered as needed or ‘‘prn’’ (Figure). There were
7242 orders written for hydralazine and 5915
orders written for labetalol. There was wide varia-
tion in the ordered frequency of as-needed adminis-
tration (Table).
There were 870 patients (39.7% of all patients)
for whom medications were ordered but never
administered (Figure). For the 1319 patients in
whom drugs were administered, 412 patients
(31.2%) received at least 1 dose of both hydral-
azine and labetalol, 581 patients (44.0%) received
at least 1 dose of hydralazine only, and 326
patients (24.7%) received at least 1 dose of labeta-
lol only. Thus, hydralazine was administered at
least once to 993 patients (75.3%) and labetalol at
least once to 738 patients (56.0%). For patients
who received treatment, the average number of
doses of hydralazine was 5.38.2 and the average
number of administered doses of labetalol was
5.67.7.
Characteristics of the Patients
Patients who received both drugs had an average
age of 60.516.5 years; hydralazine only, 62.3
17.2 years; labetalol only, 58.317.5 years; and for
those for whom orders were written but neither
drug was administered, 54.418.8 years. Com-
pared with patients who received both drugs,
patients who received neither drug were signifi-
cantly younger (P<.001 by ANOVA), while those
who received hydralazine only were older (P=.04
Figure. Intravenous hydralazine and labetalol: phar-
macy orders and drug administration in hospitalized
patients.
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by ANOVA). No other comparisons were statisti-
cally significantly different. Of the patients studied,
52.5% were men. There were no significant differ-
ences in which drug(s) were ordered or in the
number of doses administered between men and
women.
Of the 2189 patients in this study, only 64
(2.9%) had diseases for which aggressive BP-lower-
ing therapy with intravenous agents could be indi-
cated (described in the Methods section). Of these,
60 presented with subarachnoid hemorrhage, 2
with acute left ventricular dysfunction, 1 with
hypertensive encephalopathy, and 1 with aortic dis-
section. A greater proportion of the patients with
these conditions (46.9%) received labetalol plus
hydralazine than patients without such diseases
(18.0%). Hydralazine alone was administered to
14.1% of patients with concomitant diseases and
to 26.9% of those without, and labetalol alone was
administered to 12.5% of those with concomitant
illnesses and to 15.0% of those without. For pati-
ents with these potential indications for intravenous
therapy, 26.5% had drugs ordered but received nei-
ther agent, while 40.1% of patients without these
conditions received neither drug.
LOS was longer in patients in whom intravenous
antihypertensives were administered compared with
those for whom the medications were ordered but
not administered. LOS for patients for whom
hydralazine was ordered and who received at least
1 dose was 12.015.9 days but only 7.19.0 days
for those who did not receive a dose (P<.001). For
patients for whom labetalol was ordered, patients
receiving at least 1 dose had an LOS of 11.816.1
days vs 7.910.4 days for those who did not
receive a dose (P<.001).
DISCUSSION
Our findings document that treating hypertension
in the in-patient setting with intravenous hydral-
azine and labetalol is a common practice. In order
to provide as clear a picture as possible in this
exploratory study, we limited ourselves to these
two agents, and our data therefore likely represent
an estimate of the minimal frequency of treatment
of acute hypertension in the in-patient setting with
intravenous drugs. There are many other treatments
used for in-patient hypertension, including the
oral administration of hydralazine and labetalol as
well as other agents such as intravenous and oral
b-blockers, calcium channel blockers, and oral
clonidine, but since some of these agents are appro-
priately used for indications other than hyperten-
sion, we did not include them in the current study.
In our study, most patients who received treat-
ment with intravenous labetalol or hydralazine for
acutely elevated BP appeared not to have com-
monly accepted conditions warranting aggressive
antihypertensive treatment, ie, hypertensive emer-
gencies.10 Only a small minority had such illnesses,
suggesting that most of the treatment was adminis-
tered for elevated BP alone, which is consistent
with our personal observations in this hospital.
Whether the experience in our tertiary care univer-
sity hospital reflects practice in other settings, eg,
community hospitals, is unknown.
Our data indicate that hydralazine is utilized
somewhat more frequently than labetalol to treat
acutely elevated BP and that a combination of both
drugs was administered to almost a third of
patients who received treatment. The only factor
potentially related to the preference for one drug or
the other was the slightly older age of patients who
received hydralazine alone; sex did not seem to
play a role. Patients who received both drugs more
frequently had concomitant diseases for which anti-
hypertensive treatment is indicated, and they had
the longest LOS, suggesting that they may have
been sicker than those who received hydralazine or
labetalol only. Patients in whom drugs were
ordered but not administered were significantly
younger than those who received at least 1 dose of
either or both drugs, which would be consistent
with their being healthier. We do not have data
bearing on the possibility that some orders were
cancelled before drugs could be administered.
Drug treatment regimens were not ordered at
intervals consistent with expert recommendations,
which suggest that labetalol be dosed as 10- to 80-
mg intravenous boluses every 10 minutes and
hydralazine as 10- to 20-mg intravenous boluses
every 4 to 6 hours.11 Our data show that both
drugs are ordered over a wide range of dosing
intervals and that the distribution of dosing







Single dose only 724 (10.0) 390 (6.6)
Every 5 min 4 (0.1) 612 (10.3)
Every 10 min 58 (0.8) 159 (2.8)
Every 15 min 69 (1.0) 165 (2.8)
Every 1 h 2332 (32.2) 2189 (37.0)
Every 2 h 1804 (24.9) 1433 (24.2)
Every 3 h 82 (1.1) 23 (0.4)
Every 4 h 1389 (19.2) 645 (10.9)
Every 6 h 780 (10.8) 299 (5.1)
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intervals is similar for the 2 drugs, with the excep-
tion that labetalol is used more frequently at the
shortest dosing interval (5 minutes). Failure to
follow established recommendations for drug
dosing may lead to hypotension if a relatively
long-acting drug such as hydralazine is given too
frequently and ineffective therapy if a short-acting
agent such as labetalol is administered at widely
spaced intervals.
Although physicians commonly treat acute hyper-
tension in in-patients, we can find no consensus
recommendation supporting the practice. The only
statement we can find is contained in a paper that
primarily addresses well-known issues related to
treating hypertension in emergent or urgent settings,
eg, acute stroke, aortic dissection, and acute coronary
syndromes.12 The authors comment on in-hospital
hypertension and suggest that if ‘‘reactive hyperten-
sion,’’ which they define as hypertension ‘‘secondary
to pain, anxiety, respiratory distress, or urinary reten-
tion,’’ can be excluded, patients with a prior diagnosis
of hypertension should be restarted on their prehos-
pital medications. The suggested boundaries of the BP
ranges for moderate or severe elevations suggested by
Herzog and colleagues12 are not standard for the field
based on Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure (JNC 7) or
other guidelines, nor are the classifications or recom-
mendations referenced or otherwise supported.
Likewise, no rationale for the particular drugs recom-
mended is given, despite prior experience suggesting
that there are no important differences between the
pharmacologic classes of available agents used to
lower BP in the acute setting.2
The assumption that treating acute hypertension
is helpful can be questioned, and there are several
settings in which hypertension control was formerly
thought to be important where practice has chan-
ged. Treatment of asymptomatic hypertension in
the emergency department was previously com-
monly undertaken but is not currently recom-
mended.13 Similarly, there has been considerable
controversy over the years as to the appropriateness
of treating elevated BP in acute ischemic stroke:
recent guidelines of the American Stroke Associa-
tion now recommend treatment only for the most
dramatically elevated BPs (>220 mm Hg systolic or
>120 mm Hg diastolic) and, even then, the
strength of the evidence is only level V, ie, data
from anecdotal case series.14
This study represents only a very limited initial
analysis of how and why hypertension is managed
in the in-patient setting. To better understand the
practice it will be important to determine how other
antihypertensive drugs are used, to understand how
BP thresholds for drug administration are deter-
mined by clinicians and to extend observations
beyond a single tertiary care hospital. We would also
like to understand the impact of concomitant diag-
noses and clinical scenarios and to determine
whether treatment of elevated BP in in-patients
is beneficial or harmful. Finally, there are costs
associated with in-patient pharmacologic treatment,
including the costs of drug acquisition and adminis-
tration as well as a potential impact on hospital LOS
and technology utilization.
In the absence of any outcome data supporting a
benefit of treating acutely elevated BP in hospital-
ized patients, and in light of some suggestions that
acutely lowering BP may be harmful,3–5 it would
seem reasonable to limit the use of parenteral ther-
apy to situations in which acute target organ dam-
age is suspected and not as a standing ‘‘prn’’ order
targeted to elevated BP above a threshold level.
While there is a paucity of data that even in those
settings treatment is useful, there is a reasonable
expectation of doing more good than harm. In the
nonemergent in-patient setting, rather than ‘‘treat-
ing the numbers,’’ the goal should be to facilitate
long-term management of hypertension, which has
been unequivocally shown to improve outcomes.
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